Skip to main content
BioArctic logo

BioArctic — Investor Relations & Filings

Ticker · BIOA ISIN · SE0010323311 LEI · 549300Y0OI2WVUNHLC33 ST Professional, scientific and technical activities
Open in API
Filings indexed 432 across all filing types
Latest filing 2024-06-28 Regulatory Filings
Country SE Sweden
Listing ST BIOA

About BioArctic

https://www.bioarctic.se/en/

BioArctic is a research-intensive biopharmaceutical company focused on developing disease-modifying treatments, biomarkers, and diagnostics for neurodegenerative diseases. The company's core strategy is based on its proprietary antibody technology, which develops unique treatments that target the misfolded and aggregated proteins considered to be the underlying cause of disorders such as Alzheimer's and Parkinson's disease. Through strategic partnerships with global pharmaceutical companies, BioArctic advances its innovative therapies from research through clinical development and commercialization, aiming to address significant unmet medical needs in neurology.

Recent filings

Filing Released Lang Actions
Leqembi[®] (lecanemab) lanserat i Kina
Regulatory Filings Classification · 1% confidence The document is titled "Pressmeddelande" (Press Release) and announces the launch of the drug Leqembi in China by the partner Eisai. It contains key business updates, pricing information, and regulatory context (mentioning approvals in US, Japan, China, South Korea). The concluding paragraph explicitly states: "Denna information är sådan information som BioArctic AB (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning." (This information is such information that BioArctic AB (publ) is obliged to disclose pursuant to the EU's Market Abuse Regulation.) This structure strongly indicates a formal regulatory announcement intended for immediate public disclosure, rather than a comprehensive financial report (like 10-K or IR) or a specific shareholder communication (like DEF 14A or AGM-R). Since it is a general regulatory announcement that doesn't fit the highly specific categories (like DIV, DIRS, CAP), the most appropriate general regulatory fallback category is RNS (Regulatory Filings). The document length (9734 chars) is substantial, but its nature is that of an immediate market disclosure.
2024-06-28 Swedish
FDA accepterar tilläggsansökan för månatlig intravenös underhållsbehandling av tidig Alzheimers sjukdom med Leqembi[®]
Regulatory Filings Classification · 1% confidence The document is titled "Pressmeddelande" (Press Release) and announces that Eisai (BioArctic's partner) has had a supplemental Biologics License Application (sBLA) for Leqembi accepted by the FDA, setting a PDUFA action date. It details the regulatory progress, clinical rationale, and commercial agreements. This type of announcement, focusing on a specific regulatory milestone or clinical update, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific, time-sensitive announcement about a drug application status rather than a comprehensive financial report (like 10-K or IR) or a general regulatory filing fallback, it fits best as an Earnings Release (ER) if it were tied to a reporting period, or more generally, a document announcing significant corporate/regulatory news. Given the options, and that it is a formal announcement of a key development (FDA acceptance/action date) often released alongside or instead of quarterly results, ER is plausible, but since it's not explicitly quarterly results, and it's a formal announcement, RNS (Regulatory Filings - general regulatory announcements) is a strong candidate. However, press releases detailing major regulatory achievements or clinical trial updates are frequently categorized as Earnings Releases (ER) in financial databases, even if they aren't strictly quarterly earnings. Given the high significance of an FDA action date announcement, I will classify it as an Earnings Release (ER) as these often encompass major corporate news releases, or RNS as a fallback. Since it is a press release announcing a major regulatory event, and not a full financial report, RNS is the most appropriate general regulatory announcement category if ER is reserved strictly for financial performance summaries. Looking closely, it is a press release about a regulatory event, not a financial performance summary. Therefore, RNS (Regulatory Filings) is the most accurate fit for a non-standard, significant regulatory announcement that isn't a core financial report.
2024-06-10 Swedish
FDA accepts filing of Leqembi[®] (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer’s Disease
Regulatory Filings Classification · 1% confidence The document is explicitly labeled as a "Press release" and announces a regulatory milestone: the FDA's acceptance of a Supplemental Biologics License Application (sBLA) for Leqembi. It details the status of regulatory submissions (sBLA acceptance, PDUFA date set, rolling submission initiated for another application) and partnership updates. This type of announcement, which communicates key business and regulatory developments outside of routine financial reporting (like 10-K or ER), fits best under the general category for regulatory announcements or press releases that don't fit a more specific financial or governance code. Since it is a press release announcing a regulatory event (FDA acceptance), and it is not a full financial report (10-K, IR) or a management discussion (MDA), the most appropriate classification is Regulatory Filings (RNS), which serves as a broad category for such announcements not covered by other specific codes. It is not an Earnings Release (ER) as it focuses on regulatory acceptance, not financial results.
2024-06-10 English
Leqembi[®] godkänt för behandling av Alzheimers sjukdom i Sydkorea
Regulatory Filings Classification · 1% confidence The document is titled "Pressmeddelande" (Press Release) and announces a specific corporate event: the approval of the drug Leqembi in South Korea by the MFDS. It includes contact information for Investor Relations and is explicitly stated to be information that BioArctic AB is obligated to disclose under the EU Market Abuse Regulation, published on a specific date and time. This format—a brief, timely announcement of a significant event (regulatory approval/business development) intended for immediate public dissemination—is characteristic of a general regulatory announcement or press release, rather than a comprehensive financial report (like 10-K or IR) or a specific shareholder communication (like DEF 14A or AGM-R). Since it is a formal, mandatory disclosure that doesn't fit the more specific categories like ER (Earnings Release) or CAP (Financing Update), the most appropriate general category is Regulatory Filings (RNS). It is not an announcement *about* a report being published (RPA), but the announcement itself.
2024-05-24 Swedish
Leqembi[®] approved for the treatment of Alzheimer’s disease in South Korea
Regulatory Filings Classification · 1% confidence The document is explicitly titled "Press release" and announces a specific corporate event: the approval of Leqembi® in South Korea by the Ministry of Food and Drug Safety (MFDS). It contains contact information for Communications and IR, and is issued under the EU Market Abuse Regulation, indicating it is a timely, material disclosure. This format is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (like 10-K or IR) nor a presentation (IP), and it announces a significant business development rather than just a dividend or management change, it fits best as a general material announcement. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for significant, non-standardized corporate news releases that aren't explicitly earnings or capital structure changes. However, since it is a press release announcing a major regulatory milestone (drug approval), it is a material event disclosure. If 'ER' is strictly for financial results, RNS is the best fit for this type of material news announcement that isn't covered by other specific codes.
2024-05-24 English
Bulletin from the Annual General Meeting in BioArctic AB (publ)
AGM Information Classification · 1% confidence The document is explicitly titled 'Bulletin from the Annual General Meeting in BioArctic AB (publ)' and details the resolutions passed during that meeting, such as the adoption of financial statements, election of board members, approval of remuneration, and authorization for share issues/incentive programs. This content directly corresponds to the activities and outcomes of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R).
2024-05-22 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.